Skip To Main Content
David Sans on Muck Rack

David Sans

(He/Him)
New York
As seen in: The Wall Street Journal, PR Newswire, GlobeNewswire, Capital Press, BioSpace, OC Today-Dispatch
Covers:  David started as Sr. Medical Scientist at Novartis during the launch of Glivec® (Imatinib) in Switzerland, Dir. of Market Analytics at Pfizer during the launch or Rebif® (interferon beta-1a for MS)
Back to David Sans’s profile

David Sans’s Biography

David Sans, PhD, FAARM MBA
Chief of Corporate Development
David Sans, PhD, FAARM MBA joined Calidi in August of 2022 as Chief Corporate Development bringing with him many years of experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies. David oversees a multi-year, multi-target discovery and development-stage collaborations across therapeutic areas with Pharma spearheading and driving a wide range of industry collaborations for the Company.

Previously, David served as Head of Market Analytics at Pfizer during the launch of Rebif® (interferon beta-1a for MS) and Macugen® (pegaptanib) and as Sr. Medical Scientist at Novartis in Basel, Switzerland during the launch of Glivec® (imatinib) and David served as an Executive Officer at Mount Sinai Health Systems completing Business Development transactions with Philips, LabCorp, and Agilent. David is also a Board Member of the Lymphatic Education & Research Network in New York.

Dr. Sans holds a Ph.D. in Chemical Engineering from Unierstiat Ramon Llul in collaboration with the ETH in Zürich, an MBA in Business Law from Fordham in NYC, is the recipient of the Don Sheehan International Scholarship to the Wharton School of Business in Philadelphia, holds a Fellowship in Anti-Aging and Regenerative Medicine from the American Academy and Board of Regenerative Medicine and passed the all FINRA exams for Series 7, 63, 17 and 55.